Peptide experiences.

Retatrutide for sleep apnea: what the TRIUMPH-OSA trials found (2026)

In two phase 3 trials (NEJM, reported Oct 2026), retatrutide cut sleep apnea events by up to 34.3 per hour versus 9.9 with placebo in adults without diabetes, and by about 25 per hour versus 10.3 in adults with type 2 diabetes, over 80 weeks. Weight loss was 12–22%. It is still investigational: not FDA-approved and not legally available outside trials.

Peptides and teeth: what works for enamel, gums and oral health (2026)

A few peptide-based dental products are real: P11-4 helps repair early, non-cavitated enamel decay (best with fluoride), Emdogain aids gum regeneration in surgery, and CPP-ACP pastes support remineralization. None regrows a tooth. Injectable research peptides like BPC-157 or TB-500 have only animal data for gums. On GLP-1s, watch for dry mouth and reflux, and tell your dentist before sedation.

Oral minoxidil for hair loss: what the evidence actually supports (2026)

Oral minoxidil is the most widely used hair-loss treatment never approved for hair loss. Prescribed off-label at 0.25-5 mg daily, reviews report efficacy comparable to topical minoxidil with better adherence and lower cost. Nearly all of that evidence is retrospective, which is why its commonest side effect is reported at 15% in chart reviews and 71.6% in a survey that asked women directly.

Veradermics' hair-loss pill cleared Phase 3. It's minoxidil (2026)

In 536 men, VDPHL01 beat placebo decisively — 28.6 hairs/cm² once daily and 36.4 twice daily versus 6.6 for placebo at six months, p<0.0001, with separation visible by Month 2. The part most coverage buried: VDPHL01 is an extended-release oral formulation of minoxidil, a drug dermatologists already prescribe off-label. What is new is not the molecule but the registration trials — over 1,600 participants across three studies.

Are peptides safe for older adults? What the evidence does and doesn't say (2026)

For most compounds people ask about, nobody knows — the trials were never run, or were run in people decades younger. The approved GLP-1 drugs are the partial exception, and their evidence in older adults carries a real warning: muscle mass, grip strength and gait speed decline, and fragility fracture risk is modestly elevated (HR 1.11 in a cohort of over 46,000 adults aged 65+). Age changes the consequences of being wrong, not just the dose.

One in eight teenagers on a GLP-1 got a vitamin D deficiency diagnosis. Fewer than one in four saw a dietitian

A 2026 analysis of US insurance claims followed 2,031 adolescents aged 10-17 for a year after starting a GLP-1. Within that year 16.9% picked up a nutritional deficiency diagnosis, most often vitamin D at 12.4%. But it is claims data with no control group, deficiencies were counted from billing codes rather than blood tests, and 78.6% of the cohort was on liraglutide rather than the drugs teenagers start today. The finding that needs no caveats is the other one: only 23.3% saw anyone about nutrition within 180 days, and those who did waited an average of 149 days.